QVT Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

QVT Financial’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-371,617	Closed	-$4.85M	–	52
2018 Q3	$4.85M	Hold	371,617	–	–	1.25%	25
2018 Q2	$4.26M	Sell	371,617 -359,893	-49%	-$4.49M	1.22%	29
2018 Q1	$7.83M	Sell	731,510 -122,375	-14%	-$1.07M	0.82%	26
2017 Q4	$5.48M	Sell	853,885 -5,507	-0.6%	-$42.5K	0.31%	39
2017 Q3	$6.65M	Sell	859,392 -501,255	-37%	-$3.13M	0.25%	39
2017 Q2	$5.66M	Hold	1,360,647	–	–	0.15%	48
2017 Q1	$6.94M	Buy	1,360,647 +703,389	+107%	+$3.08M	0.22%	49
2016 Q4	$2.66M	Sell	657,258 -64,975	-9%	-$312K	0.08%	77
2016 Q3	$5.09M	Sell	722,233 -61,412	-8%	-$468K	0.19%	57
2016 Q2	$6.39M	Hold	783,645	–	–	0.44%	53
2016 Q1	$6.37M	Buy	783,645 +118,079	+18%	+$966K	0.39%	60
2015 Q4	$8.03M	Buy	665,566 +315,566	+90%	+$3.09M	0.45%	55
2015 Q3	$4.19M	Hold	350,000	–	–	0.14%	75
2015 Q2	$6.42M	Buy	+350,000	New	+$6.01M	0.1%	67

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial's ADAP Position: Q4 2018 in Review

QVT Financial sold out of Adaptimmune Therapeutics (ADAP) in Q4 2018, closing a stake of 371,617 shares — an estimated $4.85M sold.

QVT Financial first reported a position in ADAP in Q2 2015 and held it in 14 quarters. The position peaked at $8.03M in Q4 2015. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2018.

QVT Financial reported no remaining Adaptimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
QVT Financial sold 371,617 Adaptimmune Therapeutics shares in Q4 2018, an estimated $4.85M.
QVT Financial first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 14 quarters.
QVT Financial's Adaptimmune Therapeutics position peaked at $8.03M in Q4 2015.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2018.

Based on QVT Financial's 13F filing for Q4 2018, filed 14 Feb 2019.